Abstract: Gastrin-independent gastric neuroendocrine tumors (GNETs) are highly malignant. Radical resections and lymphadenectomy are considered to be the only possible curative treatment for these tumors. However, the prognosis of gastrin-independent GNETs is not well defined. In this study, we identified prognostic factors of locoregional gastrin-independent GNETs.
INTRODUCTION
G astric neuroendocrine tumors (GNETs) are a rare type of tumor. These tumors arise from enterochromaffin-like cells that play a role in regulating gastric acid production. GNETs have increasingly been recognized because of the widespread use of upper gastrointestinal endoscopy. 1 According to Surveillance, Epidemiology, and End Results (SEER) database, the morbidity of GNETs has increased 10 times over the past 35 years. [2] [3] [4] GNETs comprise distinct tumor entities that differ in biological behavior and prognosis. 5 GNETs are classified into gastrin-dependent and gastrinindependent types, 6 which range from benign to highly malignant biological behavior. Managing GNETs is affected by epidemiological, pathophysiological, endoscopic, and histological differences. Radical resections and lymphadenectomy are considered to be the only possible curative treatment of gastrin-independent GNETs. 7 The prognosis of patients with gastrin-independent GNETs after surgery is not well defined because only a few studies have been conducted. The most commonly utilized scheme for the prognosis of these patients is the American Joint Committee on Cancer (AJCC) tumor, node, and metastasis (TNM) staging system 8 and European Neuroendocrine Tumor Society (ENETS) Consensus Guidelines. 9 Although several tumorspecific morphological factors are associated with prognosis (e.g., tumor grading), other prognostic factors are not well defined mostly because of the small sample size in majority of the studies. In this work, we conducted a retrospective study to identify the prognostic factors of patients with locoregional gastrin-independent GNETs.
METHODS Patients
With the approval of the Institutional Review Board, we retrospectively reviewed 74 consecutive surgical cases of gastrin-independent gastric neuroendocrine neoplasms (GNENs) registered between January 2000 and December 2014 at the Department of Abdominal Surgery in the Cancer Hospital of the Chinese Academy of Medical Sciences (China). Preoperative abdominal computed tomography (CT) scans were evaluated for indication for surgery. The general situation, presenting signs and symptoms, associated disease, tumor characteristics (number, size, site, and invasion), immunohistochemistry, and patient outcome, was analyzed, because lots of the patients' preoperative diagnoses were ''gastric cancer,'' and octreotide scanning had not been widely used in China in previous years. Octreotide scanning was employed to exclude potential metastatic disease in 21 patients before surgery. After excluding 8 patients with distant metastases, 66 patients were finally examined. Clinical information was obtained from medical records.
Surgical Treatment and Pathological Examination
All the patients were surgically treated to achieve radical resections. Radical resections, which are referred to as gastric resection and D2 lymphadenectomy, were performed by experienced surgeons following the Japanese Gastric Cancer Association (JGCA) guidelines. Medicine oncologists designed the adjuvant treatment for all the patients. As there is no standard adjuvant therapy for gastrin-independent GNET patients, chemotherapy was advised if the patients had lymphatic metastasis or serosa invasion. Radiotherapy combined with chemotherapy was given to patients who had residual tumors after surgeries. The regimen of chemotherapy was EP (VP16 plus DDP) referring to the regimen of small cell lung cancer, 8 or other regimen including oxaliplatin, adriamycin, or paclitaxel.
Diagnosis of GNET was developed by pathologists according to the 2010 World Health Organization classification for neuroendocrine tumor. Pathological specimens were stained by hematoxylin-eosin. Diffuse and intense immunoreactivity of at least one of the well-known endocrine markers, namely, synaptophysin (Syn) and chromogranin A (CgA), confirmed the endocrine differentiation of tumor cells. Neural cell adhesion molecule Cluster of Differentiation 56 (CD56) was the auxiliary marker of CgA and Syn.
Follow-Up and Data Analysis
The follow-up program consisted of CT scans and endoscopic examinations every 6 months, blood tests, type-B ultrasonic, and chest radiograph every 3 months. Data were analyzed using SPSS 20.0 software. Overall survival was defined as the date of surgery to the date of death or the date of last follow-up for living patients. The Kaplan-Meier method was adopted to calculate cumulative survival, and the log rank test was used to analyze differences. The Cox proportional hazards regression model was used to identify independent prognostic factors. P < 0.05 was considered statistically significant.
RESULTS

Clinicopathological Outcomes
Gastrin-independent GNETs were common in aged (!60 years) males. Comorbidity rate was 21.2% (n ¼ 14). Approximately two-thirds of the cases were located in the fundus or cardia (n ¼ 46). Overall, most of the patients exhibited symptoms attributable to mass effect, with dysphagia and abdominal pain being the most common presenting manifestations (n ¼ 29 and 19).
Borrmann type II (ulcerative, with elevated distinct border) was the most common type and observed in 32 patients. CEA and CA19-9 (carbohydrate antigen 19-9) levels were elevated in 6 patients. Pernicious anemia was observed in 8 patients (Table 1) .
Surgery and Pathological Outcome
Among all the participants, 57 (86.4%) patients received radical resections, 7 (10.6%) with palliative resection, 1 (1.5%) who had occlusion symptom with gastrojejunostomy, and 1 (1.5%) who had asymptomatic disease with exploration surgery. On purpose to reduce tumor burden and improve the effect of chemotherapy, palliative resections (including R1 or R2 operation) were performed when the tumors cannot be completely removed during operations, because of tumor invasion or encasement of major vessels.
The tumors appeared large (>5 cm) and single. Lymphatic metastases and serosa invasion were found in 57 and 24 patients, respectively. Seven and 59 patients were classified as stages II and III, according to the AJCC TNM Staging System for neuroendocrine tumors (stomach). Seven patients exhibited cancerous nodules. A total of 50 patients received adjuvant therapy, including chemotherapy and radiation therapy, after the operations. As there is no standard adjuvant therapy for gastrin-independent GNET patients, chemotherapy was advised if the patients had lymphatic metastasis or serosa invasion. Radiotherapy combined with chemotherapy was given to patients who had residual tumors after surgeries. The regimen of chemotherapy was EP (VP16 plus DDP) referring to the regimen of small cell lung cancer, or fluorouracil-based chemotherapy referring to the regimen of gastric cancer. The details of the pathological item, including mean tumor size, number of tumors, Ki-67 index, mitotic count in 10 High power field (HPF), and histological grade, are listed in Table 2 .
Immunohistochemistry (IHC) found 66 patients to be Syn positive. CgA, neuron-specific enolase (NSE), and CD56 were detected positive in 53, 60, and 50 patients, respectively. The results of IHC detection of specific immunity indicators are summarized in Table 3 .
Survival and Prognostic Factors
Follow-up was long-term in 62 of 66 patients. The median survival time of these patients was 19.0 months (IQR, 11.0-38.0). The 1-, 3-, and 5-year survival rates were 72%, 34%, and 28%, respectively.
An analysis was performed on the clinical, surgical, and pathological characteristics to identify the prognostic factors associated with survival. Univariate analysis confirmed that patients with radical resection, early TNM stage, and CgA positive exhibited higher survival rates than those with other types. However, elevated serum CEA level, lymphatic metastases or serosa invasion, and CD56 positive were poor predictors for survival (all P < 0.05). The statistical results for survival time and other data are provided in Tables 1-3 . The survival curves are shown in Figure 1 .
According to the Cox proportional hazards regression model, which removed the confounding factors, CEA level (P ¼ 0.04), radical resection (P ¼ 0.04), and CD56 positive (P ¼ 0.016) had a significant effect on the overall survival rate (Table 4) .
To avoid the possible confounding effects of radical resection, we excluded locoregional gastrin-independent GNETs cases treated with palliative resection (n ¼ 7), gastrojejunostomy (n ¼ 1), exploration (n ¼ 1), and analyzed 57 patients with radical resection. Univariate analyses using a Cox regression model showed that CEA level (P ¼ 0.031) and CgA expression (P ¼ 0.033) were significantly associated with overall survival (OS) ( Table 5 ). However, TNM stage, lymphatic metastasis, serosa invasion, or CD56 expression were not associated with OS (P > 0.05). CEA level (P ¼ 0.033) and CgA expression (P ¼ 0.035) remained significant in multivariate analyses (Table 5) .
DISCUSSION
Approximately 14% to 25% of GNETs are classified as gastrin-independent; these GNETs are large (>2 cm, mean 5.1 cm), usually occur singly, and grow from the gastric body/ fundus in the context of normal (nonatrophic) surrounding mucosa. 10 GNETs can be divided into 3 types according to ENETS Consensus Guidelines. 9 Type I and II GNETs are gastrin-dependent, whereas Type III is gastrin-independent. Gastrin-dependent GNETs initiate because of hypergastrinemia causing hyperplasia of precursor enterochromaffin-like (ECL) cells. The hormone gastrin normally acts on ECL cells to regulate gastric acid production. 11 The hypergastrinemia of gastrin-dependent GNETs are caused by the conditions associated with achlorhydria, such as chronic atrophic gastritis, vagotomy, and chronic acid suppression treatment, or autonomous gastrin secretion from a gastrinoma (Zollinger-Ellison syndrome) or multiple endocrine neoplasm type 1.
12-14 However, gastrin-independent GNETs occur sporadically without evidence of a predisposing condition, like atrophic gastritis or a gastrinoma, that lead to hypergastrinemia. There is an absence of ECL hyperplasia in the corpus mucosa that is evident in gastrin-dependent GNETs. 15 In contrast to gastrin-dependent GNETs, gastrin-independent GNETs may be aggressive and mimic the course of gastric adenocarcinoma. These GNETs require radical oncological therapies. The overall 5-year survival of gastrin-independent GNETs ranges from 22% to 30%, 16 which was similar to our data.
GNETs are more common in male patients. The average age of onset is 55 years. Our study showed that the male/female ratio was 5.6:1. The incidence of proximal gastric fundus and cardia region accounted for 69.7%, which is similar to those in literature. 7 The clinical symptoms of gastrin-independent GNETs lack specificity, which resemble a typical carcinoid syndrome. In this group, the main syndrome of patients was abdominal pain and dysphagia. No patient exhibited carcinoid syndrome symptoms.
Resection is the primary treatment approach for most localized carcinoid tumors. Although current options for gastrin-dependent GNETs include simple surveillance, endoscopic polypectomy, surgical excision with or without surgical antrectomy, or total gastrectomy, 17 a universal consensus on the use of surgical treatment of gastrin-independent GNET exists. Complete surgical resection is associated with better long-term survival. 18 Radical resections, which are referred to as gastric resection and D2 lymphadenectomy, were performed by experienced surgeons following the JGCA guidelines. Gastrin-independent GNETs represent highly malignant tumors with strong invasive and metastatic potential although the locoregional diseases are usually presented with extensive local lymph node metastasis and invasion to adjacent organs. The goal of radical resections is impossible to achieve in every localized gastrinindependent GNET patients. Our study showed that 57 of 66 patients received radical surgeries and achieved better survival than those with palliative surgeries (Figure 1 ). Surgical resection is only advised for G1 and G2 patients with liver metastases. 19, 20 However, Du et al 21 reported that grade 3 gastroenteropancreatic neuroendocrine tumor patients with liver metastases also benefit from surgery. For locoregional unresectable and/or metastatic carcinoid tumors, cytoreductive surgery or ablative therapies such as radiofrequency ablation or cryoablation may be considered if near-complete treatment of tumor burden can be achieved because of the poor efficacy of chemotherapy and radiotherapy. [22] [23] [24] [25] But it remains controversial. In recent years, increasing attention has been given to the relation between CD56 and tumor progression. CD56 expression is an independent adverse risk factor for patients with acute myeloid leukemia with t (8;21) 26 and patients with acute promyelocytic leukemia with high initial white blood cell counts. [27] [28] [29] Simultaneous expression of CD56 and CgA (P < 0.04) is significantly associated with poor outcomes in large-cell neuroendocrine carcinoma, which is a rare neuroendocrine pulmonary malignancy. 30 Neural cell adhesion molecule, also called CD56, is a group of cell surface glycoproteins that are involved in direct cell-cell adhesion and induce biological effect. It is involved in the adhesion, detachment, and aggregation of malignant cells.
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CD56 of neuroendocrine neoplasms is highly expressed on immunophenotyping. [32] [33] [34] Sufficient and deep layer of IHC detection helps improve the diagnostic accuracy for NETs. Syn, CgA, and CD56 are neuroendocrine differentiation markers that are important for diagnosing neuroendocrine carcinoma, particularly CgA, which is secreted by the neuroendocrine cells. However, scarcely any research has determined the association of IHC markers with prognosis in GNET patients. Our study found that CD56 and CgA expression were associated with survival of GNETs. Multivariate analysis indicated that CD56 is an independent prognostic factor. CD56 may be a reliable targeted protein for therapy. Geertsen et al 35 reported that IFN-gamma exhibits a weak upregulating effect in CD56 expression. IMGN901 (lorvotuzumab mertansine), a new antibody-drug conjugate, was developed to target and kill CD56-positive cancer cells. 36 As it had been found that, the immunogenicity of CgA in NET tissue decreased or even disappeared with the decreasing of tumor's differentiation. Maybe the morphology and function of well-differentiated NET cells are similar with normal neuroendocrine cells, but secretory granules in poorly differentiated NET cells are rare, 37 indicating that expression of CgA correlated with the differentiation of NET and CgA may be a prognostic marker of gastroenteropancreatic neuroendocrine tumor (GEP-NET). There have been several studies reporting that serum CgA levels are associated with survival of GEP-NET patients. 38, 39 But few studies reported the relationship of CgA expression on immunohistochemical staining and prognosis in NET patients. Wang et al 40 analyzed the patients with gastrointestinal NETs and found that the survival rate after 1 and 2 years for patients with CgA expression was significantly higher than that for patients without CgA expression. Their finding corroborates our further result of the multivariate analysis of 57 patients with locoregional gastrinindependent GNET who received radical resections. After precluding 9 patients who received nonradical resection, we found that CgA expression and CEA level are independent prognostic factors.
The association between GNETs and tumor markers has not been well investigated because of its rarity. The concept of serum tumor marker represents a quantifiable assessment of the tumor burden at that time. Using tumor markers involve several aspects, such as determination of cancer risk, screening, diagnosis, prognosis, prediction of response to therapy, and monitoring disease course. [41] [42] [43] Blood CgA is the best tumor marker for neuroendocrine carcinoma. The specificities of biomarkers in GEP-NET patients were 86% for CgA, 100% for NSE, 91% for CEA, and 100% for 5-hydroxyindoleacetic acid (5-HIAA). The corresponding sensitivities were 68% for CgA, 33% for NSE, 15.4% for CEA, and 35% for 5-HIAA. 44 Serum CgA test was only performed in very few hospitals in China. Thus, in our center, CEA and CA19-9 were routinely tested for each patient with GNET, although these markers are not as sensitive as CgA for GNETs. CEA is a carbohydrate antigen extracted from the tissues of patients with digestive tract cancer, and it is a related antigen of digestive tract neuroendocrine carcinoma. When a cell is cancerous, the protease and activity of the enzyme in the cell membrane increase and the cell cytoskeleton is destroyed, causing the cell surface antigen to litter. Thus, the serum CEA content increases. We are interested to determine whether CEA level is an independent prognostic factor of GNETs through multivariate analysis. We suggest that serum CEA should be tested in every GNET patient. In summary, serum CEA can be utilized to monitor the treatment for patients with gastrointestinal neuroendocrine carcinoma, tumor recurrence, and metastasis. Clinical doctors commonly use tumor invasion, lymphatic metastases, and TNM stage to anticipate survival because the biological behavior of gastrin-independent GNETs is sometimes similar to gastric adenocarcinoma. However, we should also focus on the unique factors in GNETs, such as Ki-67 index and IHC markers. Aside from these prognostic factors, Ki-67 index is a widely accepted factor in predicting survival in NETs. 23 Ki-67 index was not an independent prognostic factor in our study because almost all the Ki-67 index of our patients were high. 
